D. E. Shaw & Co., Inc. Rubius Therapeutics, Inc. Transaction History

D. E. Shaw & Co., Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$0.79 - $5.98 $49,427 - $374,144	62,566 Added 114.01%	117,446 $100,000
Q1 2022 May 16, 2022	SELL	$4.25 - $10.4 $157,403 - $385,174	-37,036 Reduced 40.29%	54,880 $302,000
Q4 2021 Feb 14, 2022	SELL	$9.68 - $17.74 $109,171 - $200,071	-11,278 Reduced 10.93%	91,916 $890,000
Q3 2021 Nov 15, 2021	SELL	$17.6 - $25.91 $461,560 - $679,489	-26,225 Reduced 20.26%	103,194 $1.85 Million
Q2 2021 Aug 16, 2021	SELL	$22.26 - $28.43 $871,612 - $1.11 Million	-39,156 Reduced 23.23%	129,419 $3.16 Million
Q1 2021 May 17, 2021	BUY	$8.02 - $32.01 $59,973 - $239,370	7,478 Added 4.64%	168,575 $4.47 Million
Q4 2020 Feb 16, 2021	BUY	$4.23 - $8.73 $523,454 - $1.08 Million	123,748 Added 331.33%	161,097 $1.22 Million
Q3 2020 Nov 16, 2020	BUY	$4.65 - $6.25 $92,804 - $124,737	19,958 Added 114.76%	37,349 $187,000
Q2 2020 Aug 14, 2020	BUY	$4.01 - $6.88 $69,737 - $119,650	17,391 New	17,391 $104,000

325

Ticker RUBY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,357,000
Description
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatmen...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.